GlassScriptPhysician profile
Kristopher B Meadows
NPI 1700170602
$2,004.75
in general payments reported to CMS, 2019-2025
25 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.32 · 2020: $27.10 · 2021: $220 · 2022: $214 · 2023: $219 · 2024: $660 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $428.52 | 2021-2025 | |
| Novo Nordisk INC | $405.45 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $151.78 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $147.92 | 2023-2025 | |
| Abbvie INC. | $119.98 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $104.39 | 2023-2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $70.02 | 2019-2023 | |
| Amgen INC. | $69.56 | 2023-2024 | Evenity, Prolia, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $65.41 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.13 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $48.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Melinta Therapeutics, LLC | $43.22 | 2019-2020 | |
| Lundbeck LLC | $40.02 | 2023-2024 | Rexulti |
| Dexcom, INC. | $31.00 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $29.76 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $28.82 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $26.15 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $21.44 | 2025 | Keveyis |
| Portola Pharmaceuticals, LLC | $20.58 | 2019 | |
| Almatica Pharma LLC | $19.67 | 2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $18.72 | 2024 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.97 | 2024 | Xifaxan, Trulance |
| Ferring Pharmaceuticals INC. | $15.16 | 2023 | Rebyota |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2025 | Zoryve |
| Shield Therapeutics INC | $13.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.